Skip to main content
Premium Trial:

Request an Annual Quote

Roche Epstein-Barr Virus Quantitative Test Receives FDA Clearance

NEW YORK – Roche announced Wednesday its Cobas Epstein-Barr Virus test was authorized for use by the US Food and Drug Administration.

The quantitative test uses dual target technology to help clinicians monitor transplant patients who are at risk of complications from infections or reactivations of the virus. The PCR viral load test runs on Roche's Cobas 6800 and Cobas 8800 Systems and can be run simultaneously with other virology tests, the company said. It has been calibrated to the World Health Organization International Standard, meaning results are reported in international measures. The test's limit of detection is 18.8 IU per milliliter. 

Roche's test previously received breakthrough device designation from the FDA and obtained CE marking last year. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more